S&P 500   4,593.68 (+0.57%)
DOW   36,223.95 (+0.76%)
QQQ   389.86 (+0.26%)
AAPL   191.04 (+0.57%)
MSFT   375.06 (-1.02%)
META   324.89 (-0.69%)
GOOGL   131.74 (-0.60%)
AMZN   147.02 (+0.64%)
TSLA   238.23 (-0.77%)
NVDA   468.11 (+0.09%)
NIO   7.22 (-0.69%)
BABA   74.09 (-1.06%)
AMD   121.00 (-0.13%)
T   16.70 (+0.78%)
F   10.57 (+3.02%)
MU   76.02 (-0.13%)
CGC   0.62 (+10.48%)
GE   122.51 (+0.58%)
DIS   92.35 (-0.37%)
AMC   6.96 (+4.66%)
PFE   28.82 (-5.42%)
PYPL   59.43 (+3.16%)
XOM   102.95 (+0.20%)
S&P 500   4,593.68 (+0.57%)
DOW   36,223.95 (+0.76%)
QQQ   389.86 (+0.26%)
AAPL   191.04 (+0.57%)
MSFT   375.06 (-1.02%)
META   324.89 (-0.69%)
GOOGL   131.74 (-0.60%)
AMZN   147.02 (+0.64%)
TSLA   238.23 (-0.77%)
NVDA   468.11 (+0.09%)
NIO   7.22 (-0.69%)
BABA   74.09 (-1.06%)
AMD   121.00 (-0.13%)
T   16.70 (+0.78%)
F   10.57 (+3.02%)
MU   76.02 (-0.13%)
CGC   0.62 (+10.48%)
GE   122.51 (+0.58%)
DIS   92.35 (-0.37%)
AMC   6.96 (+4.66%)
PFE   28.82 (-5.42%)
PYPL   59.43 (+3.16%)
XOM   102.95 (+0.20%)
S&P 500   4,593.68 (+0.57%)
DOW   36,223.95 (+0.76%)
QQQ   389.86 (+0.26%)
AAPL   191.04 (+0.57%)
MSFT   375.06 (-1.02%)
META   324.89 (-0.69%)
GOOGL   131.74 (-0.60%)
AMZN   147.02 (+0.64%)
TSLA   238.23 (-0.77%)
NVDA   468.11 (+0.09%)
NIO   7.22 (-0.69%)
BABA   74.09 (-1.06%)
AMD   121.00 (-0.13%)
T   16.70 (+0.78%)
F   10.57 (+3.02%)
MU   76.02 (-0.13%)
CGC   0.62 (+10.48%)
GE   122.51 (+0.58%)
DIS   92.35 (-0.37%)
AMC   6.96 (+4.66%)
PFE   28.82 (-5.42%)
PYPL   59.43 (+3.16%)
XOM   102.95 (+0.20%)
S&P 500   4,593.68 (+0.57%)
DOW   36,223.95 (+0.76%)
QQQ   389.86 (+0.26%)
AAPL   191.04 (+0.57%)
MSFT   375.06 (-1.02%)
META   324.89 (-0.69%)
GOOGL   131.74 (-0.60%)
AMZN   147.02 (+0.64%)
TSLA   238.23 (-0.77%)
NVDA   468.11 (+0.09%)
NIO   7.22 (-0.69%)
BABA   74.09 (-1.06%)
AMD   121.00 (-0.13%)
T   16.70 (+0.78%)
F   10.57 (+3.02%)
MU   76.02 (-0.13%)
CGC   0.62 (+10.48%)
GE   122.51 (+0.58%)
DIS   92.35 (-0.37%)
AMC   6.96 (+4.66%)
PFE   28.82 (-5.42%)
PYPL   59.43 (+3.16%)
XOM   102.95 (+0.20%)

Rhythm Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RYTM)

$33.63
+0.20 (+0.60%)
(As of 03:27 PM ET)
Compare
Today's Range
$32.96
$34.04
50-Day Range
$21.39
$34.64
52-Week Range
$15.50
$35.29
Volume
189,566 shs
Average Volume
665,134 shs
Market Capitalization
$1.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.71

Rhythm Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
11.5% Upside
$37.71 Price Target
Short Interest
Bearish
15.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.80
Upright™ Environmental Score
News Sentiment
0.36mentions of Rhythm Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$724,583 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.21) to ($2.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

806th out of 949 stocks

Pharmaceutical Preparations Industry

393rd out of 447 stocks


RYTM stock logo

About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

RYTM Stock Price History

RYTM Stock News Headlines

Rhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 1-Year High at $35.29
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
RYTM Rhythm Pharmaceuticals, Inc.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
See More Headlines
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RYTM
Employees
177
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.71
High Stock Price Target
$56.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+12.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-181,120,000.00
Net Margins
-299.33%
Pretax Margin
-298.74%

Debt

Sales & Book Value

Annual Sales
$23.64 million
Book Value
$3.34 per share

Miscellaneous

Free Float
56,318,000
Market Cap
$1.98 billion
Optionable
Optionable
Beta
1.66
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. David P. Meeker M.D. (Age 69)
    Chairman, President & CEO
    Comp: $1.17M
  • Mr. Hunter C. Smith M.B.A. (Age 54)
    CFO & Treasurer
    Comp: $692.2k
  • Mr. Joseph Shulman (Age 48)
    Chief Technical Officer
    Comp: $608.2k
  • Mr. Yann Mazabraud (Age 50)
    Executive VP & Head of International
    Comp: $747.43k
  • Ms. Jennifer L. Chien (Age 48)
    Executive VP & Head of North America
    Comp: $644.2k
  • Mr. Christopher German (Age 52)
    Corporate Controller, Principal Accounting Officer & Executive Director
  • Mr. David Connolly
    Head of Investor Relations & Corporate Communications
  • Mr. Jim Flaherty
    Senior VP & General Counsel
  • Ms. Sarah Ryan
    Vice President of Sales & Marketing
  • Ms. Pamela J. Cramer (Age 49)
    Chief Human Resources Officer














RYTM Stock Analysis - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RYTM shares.
View RYTM analyst ratings
or view top-rated stocks.

What is Rhythm Pharmaceuticals' stock price target for 2024?

7 Wall Street research analysts have issued twelve-month price objectives for Rhythm Pharmaceuticals' stock. Their RYTM share price targets range from $27.00 to $56.00. On average, they anticipate the company's share price to reach $37.71 in the next year. This suggests a possible upside of 11.5% from the stock's current price.
View analysts price targets for RYTM
or view top-rated stocks among Wall Street analysts.

How have RYTM shares performed in 2023?

Rhythm Pharmaceuticals' stock was trading at $29.12 on January 1st, 2023. Since then, RYTM stock has increased by 16.2% and is now trading at $33.83.
View the best growth stocks for 2023 here
.

Are investors shorting Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 9,410,000 shares, a drop of 19.2% from the October 31st total of 11,650,000 shares. Based on an average daily volume of 571,000 shares, the days-to-cover ratio is currently 16.5 days.
View Rhythm Pharmaceuticals' Short Interest
.

When is Rhythm Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our RYTM earnings forecast
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.76) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.76). The company earned $22.50 million during the quarter, compared to analysts' expectations of $22.18 million. Rhythm Pharmaceuticals had a negative net margin of 299.33% and a negative trailing twelve-month return on equity of 85.92%. Rhythm Pharmaceuticals's revenue was up 425.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.79) EPS.

What ETFs hold Rhythm Pharmaceuticals' stock?

ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).BlackRock Future Health ETF (BMED).

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (13.99%), Polar Capital Holdings Plc (4.23%), Federated Hermes Inc. (3.96%), FMR LLC (1.47%), Northern Trust Corp (0.85%) and Assenagon Asset Management S.A. (0.72%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, Ra Capital Management, LP, William T Roberts and Yann Mazabraud.
View institutional ownership trends
.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RYTM) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -